The Scripps Research Institute

University of Texas System

Scripps Clinic and Research Foundation

Other

University of Pennsylvania

Temple University

Thomas S Edgington

Philip E Thorpe

Edward F Plow

Wolfram Ruf

Cheng Liu

Linda K Curtiss

Robert W Colman

Dario C Altieri

L Henry Edmunds, Jr

Janos Kappelmayer

Alvise Bernabei

Susan A Gregory

Richard Kornbluth

Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.

Combined methods for tumor coagulation and tumor treatment

The present invention relates to new agents and methods useful for preventing, treating and diagnosing diseases such as cancer. For example, the invention relates to prodrug agents useful for targeting and delivering cytotoxic drugs to cancerous cells.

Targeted delivery to legumain-expressing cells

The invention provided compositions and methods to initiate site-specific thrombosis in tumor vasculature. The present invention also provides methods for using the disclosed compositions and methods to treat tumors.

Targeted thrombosis

Combined methods and compositions for coagulation and tumor treatment

Methods and compositions for the specific coagulation of vasculature

Kits and methods for the specific coagulation of vasculature

Methods for the specific coagulation of vasculature

DNA segments that include DNA sequences defining a structural gene coding for a human tissue factor heavy chain protein and a precursor form of that protein are disclosed. Recombinant DNA molecules capable of expressing a human tissue factor heavy chain protein are also disclosed. Further disclosed are human tissue factor heavy chain binding site polypeptide analogs as well as methods for their use.

Human tissue factor related DNA segments polypeptides and antibodies

The present invention describes a mutant human tissue factor protein which binds functional Factor VII/VIIa but is substantially free of functional procoagulant cofactor activity, and compositions containing the mutant protein. Also disclosed are methods for using the mutant human tissue factor proteins, and recombinant DNA vectors for expressing the protein.

Human mutant tissue factor compositions useful as tissue factor

Tissue factor compositions and ligands for the specific coagulation of

Human tissue factor related DNA segments, polypeptides and antibodies

The present invention contemplates therapeutic compositions containing a D.sub.30 homolog capable of binding to the Mac-1 receptor D.sub.30 binding site and inhibiting fibrinogen binding to the Mac-1 receptor via the D.sub.30 binding site, Methods of inhibiting Mac-1 receptor binding to any Mac-1 ligand and methods of inhibiting Mac-1 receptor mediated inflammation within a patient by administering a D.sub.30 homolog are also contemplated,

Inhibition of Mac-1 receptor binding to fibrinogen using D.sub.30

This invention provides a method of inhibiting coagulation in extracorporeal circulation in a subject, comprising administration of a therapeutically effective amount of a monoclonal antibody which inhibits the ability of tissue factor to bind to factor VII/VIIa. The method prevents complex formation between tissue factor and factor VII/VIIa and thus inhibits coagulation of blood in extracorporeal procedures such as cardiopulmonary bypass and other shunt procedures. Anti-tissue factor monoclonal antibodies produced by hybridoma cell lines TFS-5G9 or TF9-6B4 may be used in the claimed methods.

Method of inhibiting blood coagulation in extracorporeal circulation by

Murine hybridomas producing monoclonal antibodies capable of immunoreacting with huTFh and polypeptide analogs are described. Also contemplated are immunologic methods for detecting huTF heavy chain in body fluid, detecting thrombic events in vivo, isolating coagulation factor, and neutralizing VII/VIIa coagulation factor binding in vivo.

Hybridomas producing monoclonal antibodies reactive with human

Growing community of inventors

La Jolla, CA, United States of America

Thomas S Edgington